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Introduction {#sec001}
============

The sleep-wake cycle depends on a complex and well-orchestrated neuronal circuitry involving diverse neurotransmitter signaling that induce and maintain sleep and wakefulness. Glutamate, the most excitatory neurotransmitter in the central nervous system, shows dynamic changes in its levels throughout the sleep-wake states \[[@pone.0223632.ref001]\]. In addition, it is involved in the initiation and maintaining of waking and rapid eye movement (REM) sleep \[[@pone.0223632.ref002]\]. The function of glutamate as a signaling molecule in the brain is accomplished by its multiple receptor subtypes working through selective intracellular targeting mechanisms \[[@pone.0223632.ref003]\].

The Homer protein family has been implicated in the trafficking and/or clustering of metabotropic glutamate receptors, playing roles on critical glutamatergic signaling pathways \[[@pone.0223632.ref004]\]. These proteins are encoded by three different genes ‒ *Homer1*, *Homer2* and *Homer3* ‒ predominantly expressed at the nervous system as several isoforms resulting from alternative splicing events \[[@pone.0223632.ref005]\]. Among the splicing variants, *Homer1a* is a non-constitutive short form, induced under high neuronal activity associated with decreasing glutamate signaling \[[@pone.0223632.ref006]\], identified as the most specific transcriptional marker for sleep loss \[[@pone.0223632.ref007]\]. It was already been observed an increase in the expression of this transcript variant induced by sleep deprivation; it has been proposed that its up regulation modulates the increased neuronal glutamatergic activity found in prolonged wakefulness \[[@pone.0223632.ref007]\].

Single nucleotide polymorphisms (SNPs) ‒ genomic *loci* where two or more alleles differ at a single base ‒ have been associated with complex phenotypes, providing important molecular markers and unraveling risk *loci* for disease susceptibility \[e.g. [@pone.0223632.ref008],[@pone.0223632.ref009]\]. Polymorphisms in the *HOMER1* gene have been associated with disorders and traits related to glutamate signaling dysregulation, such as schizophrenia and cocaine dependence \[[@pone.0223632.ref010]--[@pone.0223632.ref012]\]. We hypothesize that, given the importance of the glutamatergic system regulating sleep and prolonged wakefulness, genetic variation in the *HOMER1* gene might explain inter-individual variability in several sleep traits measured using polysomnography. The goal of the present study was to evaluate the association of a specific SNP in the *HOMER1* gene with specific aspects of sleep in a representative sample of the Brazilian population.

Material and methods {#sec002}
====================

Subjects {#sec003}
--------

Subjects consisted of a sample of 1,042 individuals from the São Paulo Epidemiological Sleep Study (EPISONO), a population-based survey to represent São Paulo city population, delineating the epidemiological profile of sleep disorders in a metropolitan Brazilian city according to gender, age, and socioeconomic status in 2007. All individuals answered questionnaires about socioeconomic, demographic, lifestyle and general health factors. Blood samples were collected to investigate genetic traits and polysomnographic recordings were taken to access objective sleep quality. This study was approved by the Ethics Committee of the Federal University of São Paulo (CEP 0593/06) and was registered under ClinicalTrials.gov (NCT00596713; Epidemiology of sleep disturbances among adult population of the São Paulo City). All participants signed up informed consent forms.

Polysomnography and clinical assessment {#sec004}
---------------------------------------

A full-night polysomnography was performed using a digital system (EMBLA® S7000, Embla Systems, Inc., Broomfield, CO, USA) at the sleep laboratory. Physiological variables were monitored continuously, and recordings were scored according to standardized criteria \[[@pone.0223632.ref013],[@pone.0223632.ref014]\]. Obstructive sleep apnea syndrome (OSAS) was considered positive if individuals had an apnea-hypopnea index (AHI) between 5 and 14.9 and presented at least one of the following complaints: loud snoring, daytime sleepiness, fatigue, and breathing interruptions during sleep. Subjects with an AHI ≥15 were also considered positive, regardless whether they presented complaints \[[@pone.0223632.ref015]\].

Spectral analysis of sleep EEG {#sec005}
------------------------------

A specific syntax in R (version 2.10.1) was used for the spectral analysis of the sleep electroencephalography (EEG), performed according to previously published studies \[[@pone.0223632.ref016],[@pone.0223632.ref017]\]. Briefly describing, waves from C3-A2, C4-A1, O1-A2, and O2-A1 derivations were decomposed into delta (\<4 Hz), theta (4--7.9 Hz), alpha 1 (8--9.9 Hz), alpha 2 (10--12.9 Hz), beta 1 (13--17.9 Hz), beta 2 (18--29.9 Hz), and gamma (≥30 Hz) frequency bands using fast Fourier transformation, with a sampling rate of 200 Hz, using epochs of 20 seconds. The filter settings used were in accordance to standard criteria of sleep EEG data acquisition (low frequency filter = 0.3 Hz; high frequency filter = 35 Hz; time constant = 0.3 seconds; and notch filter = 60 Hz). Artifact removal was performed as previously described \[[@pone.0223632.ref016]\].

rs3822568 genotyping {#sec006}
--------------------

Genomic DNA was extracted from the volunteers' white blood cells through the salting out of the cellular proteins and precipitation with a saturated NaCl solution \[[@pone.0223632.ref018]\]. *HOMER1* SNP rs3822568 was amplified by PCR (Polymerase Chain Reaction) using the primers H1F: `5’CCTGTTCACTGAGAAGAGCCTA3’` and H1R: `3’GAAATACAGCAGCCCGTCAT5’`, under the following thermal conditions: 5 min at 95°C; 35 cycles of 0.5 min at 95°C, 0.5 min at 66°C, and 0.5 min at 72°C; 5 min at 72°C; held at 4°C. The 25 μl PCR mixes included 2.5 μl 10X PCR buffer, 0.75 μl MgCl~2~ (1.5 mM), 0.5 μl of each primer, 0.5 μl of dNTP mix (2mM dATP, 2mM dCTP, 2mMdTTP, and 2mM dGTP), 0.25 μl of Taq DNA Polymerase, and 1.0 μl of DNA template (100ng/μl). Due to the presence of restriction sites inside the *HOMER1* sequence, genotypes were determined using the Restriction Fragment Length Polymorphism (RFLP) method. Restriction endonuclease digestions were carried out directly on PCR products in 20 μl reactions containing 0.2 μl 10X buffer solution, 0.25 μl *PvuII* (New England Biolabs), and 5.0 μl PCR product. The *PvuII* enzyme cleaves the palindromic sequence CAG\^CTG, providing a three-band profile (397pb, 218pb, and 178pb) for subjects carrying the A/G genotype; a two-band profile (218pb and 178pb) for homozyguous A/A; and the single-band profile (397pb) for homozyguous G/G. Digestion took place at 37°C for 16 hours, and the obtained profiles were visualized in 1% agarose gels, stained with ethidium bromide.

Statistical analysis {#sec007}
--------------------

The chi-square test was used to verify whether *HOMER1* genotype frequencies were distributed according to the Hardy-Weinberg Equilibrium. One-way Analysis of Variance (ANOVA) followed by Bonferroni *post hoc* test was used to verify the effect of *HOMER1* polymorphism on the z-score standardized polysomnographic parameters and sleep EEG spectral data. Also, the chi-square test was performed to compare genotype frequencies between individuals with and without OSAS. Furthermore, a set of 31 ancestry informative markers was used to estimate the genetic ancestry proportions of the population as previously described \[[@pone.0223632.ref019]\]. General linear models (GLM) were applied to verify the effect of potential confounders (age, sex, body mass index and ancestry proportions) on the genetic association results of the continuous variables. Tests were performed using PAWS 18.0 (SPSS, Inc.), with a significance level of 0.05. Results are represented as mean \[standard deviation\].

Results {#sec008}
=======

A total of 983 individuals (42.43 \[14.36\] years; 55.8% females) had valid genotypes for the *HOMER1* polymorphism rs3822568. Genotype frequencies for this SNP were 219 (22.3%), 469 (47.7%) and 295 (30.0%) for AA, AG and GG, respectively, and genotype distribution did not show deviations from Hardy-Weinberg Equilibrium (χ^2^ = 1.58; p = 0.209).

We verified the association of *HOMER1* rs3822568 genotypes with a number of polysomnographic parameters, as show in [Table 1](#pone.0223632.t001){ref-type="table"}. We found significant associations between rs3822568 and sleep latency (F~(2,980)~ = 6.389, p = 0.002), sleep efficiency (F~(2,980)~ = 2.962, p = 0.033), number of arousals per hour (F~(2,980)~ = 6.075, p = 0.002) and apnea-hypopnea index (F~(2,980)~ = 3.988, p = 0.019). In summary, GG genotype carriers showed higher sleep latency in minutes (20.48 \[29.74\]) than AG genotype carriers (14.57 \[16.23\], Bonferroni *post hoc* p = 0.001) and lower sleep efficiency (80.56 \[13.95\]) than AG genotype carriers (82.94 \[11.71\], Bonferroni *post hoc* p = 0;040). In addition, GG carriers showed lower arousals per hour index (13.27 \[9.12\]) and AHI (6.63 \[11.13\]) than AA genotype carriers (16.61 \[11.6\]; Bonferroni *post hoc* p = 0.002; and 9.89 \[14.98\]; Bonferroni *post hoc* p = 0.016, respectively). We also found a trend for association between *HOMER1* rs3822568 polymorphism and the percentage of stages N3, but no significant associations were found after the *post hoc* test ([Table 1](#pone.0223632.t001){ref-type="table"}). Also, despite the association between this SNP and the apnea-hypopnea index levels, no significant association with the presence of OSAS was found (χ^2^ = 4.104; p = 0.128).

10.1371/journal.pone.0223632.t001

###### Sleep parameters measured by polysomnography comparing the three *HOMER1* rs3822568 SNP genotypes.

![](pone.0223632.t001){#pone.0223632.t001g}

  Polysomnographic parameter    rs3822568 genotype   N                                                     Mean (SD)        F~(2,980)~   p
  ----------------------------- -------------------- ----------------------------------------------------- ---------------- ------------ -------
  Sleep latency (minutes)       AA                   219                                                   17.14 (21.82)    6.389        0.002
  AG                            469                  14.57 (16.23)                                                                       
  GG                            295                  20.48 (29.74) [\*](#t001fn002){ref-type="table-fn"}                                 
  REM sleep latency (minutes)   AA                   219                                                   98.71 (54.99)    0.596        0.551
  AG                            469                  102.03 (54.15)                                                                      
  GG                            295                  98.01 (52.22)                                                                       
  Sleep total time (minutes)    AA                   219                                                   346.19 (85.67)   2.962        0.052
  AG                            469                  347.28 (71.43)                                                                      
  GG                            295                  333.82 (80.64)                                                                      
  Sleep efficiency (%)          AA                   219                                                   81.18 (13.9)     3.433        0.033
  AG                            469                  82.94 (11.71)                                                                       
  GG                            295                  80.56 (13.95) [\*](#t001fn002){ref-type="table-fn"}                                 
  Stage 1 (%)                   AA                   219                                                   4.86 (3.72)      1.725        0.179
  AG                            469                  4.68 (3.28)                                                                         
  GG                            295                  4.33 (3.19)                                                                         
  Stage 2 (%)                   AA                   219                                                   54.87 (8.75)     0.284        0.753
  AG                            469                  54.67 (9.57)                                                                        
  GG                            295                  54.28 (9.23)                                                                        
  Stages N3 (%)                 AA                   219                                                   21.23 (7.35)     3.276        0.038
  AG                            469                  21.53 (8.23)                                                                        
  GG                            295                  22.85 (8.29)                                                                        
  REM sleep (%)                 AA                   219                                                   19.04 (6.72)     0.771        0.463
  AG                            469                  19.13 (6.48)                                                                        
  GG                            295                  18.54 (6.47)                                                                        
  Awake time (minutes)          AA                   219                                                   62.72 (50.2)     0.868        0.420
  AG                            469                  57.83 (44.73)                                                                       
  GG                            295                  59.74 (43.19)                                                                       
  Number of arousals per hour   AA                   219                                                   16.61 (11.6)     6.075        0.002
  AG                            469                  15.16 (11.69)                                                                       
  GG                            295                  13.27 (9.12) [\*](#t001fn002){ref-type="table-fn"}                                  
  Apnea-hypopnea index          AA                   219                                                   9.89 (14.98)     3.988        0.019
  AG                            469                  8.33 (13.18)                                                                        
  GG                            295                  6.63 (11.13) [\*](#t001fn002){ref-type="table-fn"}                                  

One-way ANOVA on z-score standardized measurements; SD: standard deviation; REM: rapid eye-movement.

\* Indicates p\<0.05 when compared to the other genotypes inside each variable.

To verify the effect of potential confounders on the identified associations, we fitted GLMs using *HOMER1* rs3822568 genotypes as well as sex, age, BMI and European ancestry proportion derived from ancestry informative markers as independent variables and the z-score of each significantly associated parameter in univariate analyses as dependent variables in each model. After adjustment for the studied confounders, *HOMER1* rs3822568 polymorphism was significantly and independently associated only with sleep latency, regardless of other variables in the model (p = 0.005).

Comparing the spectral power of each studied bandwidth in each sleep stage for each EEG derivation, we found significant associations between *HOMER1* rs3822568 polymorphism and theta spectral power in all EEG derivations, even after adjustment for sex, age, BMI and European ancestry proportion. Overall, GG genotype carriers showed lower theta spectral power in stage 1, stage 2 and REM sleep; however, after adjustment for potential confounders, associations remained significant only in the occipital derivations and in sleep stage 1 and REM sleep ([Table 2](#pone.0223632.t002){ref-type="table"}). No significant associations with other bandwidths were found.

10.1371/journal.pone.0223632.t002

###### Significant associations between *HOMER1* rs3822568 polymorphism genotypes and theta (4--7.9 Hz) spectral power in sleep electroencephalogram.

Results are shown by derivation and sleep stage.

![](pone.0223632.t002){#pone.0223632.t002g}

  Derivation   Sleep Stage   rs3822568 Genotype   df     F      p-value   Adjusted p-value                                                                                               
  ------------ ------------- -------------------- ------ ------ --------- ------------------ ------ ------ ------ ------- ------- ------- ---------------------------------------------- ----------------------------------------------
  O2-A1        1             173                  4.34   1.25   351       4.49               1.23   231    4.19   1.15    2,752   4.412   0.012                                          0.035 [^a^](#t002fn002){ref-type="table-fn"}
  2            188           4.24                 1.18   384    4.42      1.24               245    4.17   1.16   2,814   3.679   0.026   0.086                                          
  REM          187           4.09                 1.20   382    4.15      1.10               243    3.87   1.08   2,809   4.847   0.008   0.029 [^b^](#t002fn003){ref-type="table-fn"}   
  O1-A2        1             173                  4.48   1.14   351       4.52               1.21   231    4.25   1.19    2,752   3.769   0.024                                          0.062
  REM          187           4.29                 1.15   382    4.24      1.09               243    3.97   1.10   2,809   5.59    0.004   0.008 [^c^](#t002fn004){ref-type="table-fn"}   
  C3-A2        1             173                  3.92   1.17   351       3.95               1.11   231    3.70   1.03    2,752   3.925   0.020                                          0.089
  2            188           3.30                 1.03   384    3.40      1.04               245    3.16   0.94   2,814   4.4     0.013   0.074                                          
  REM          187           4.00                 1.06   382    4.02      1.03               243    3.80   1.02   2,809   3.826   0.022   0.077                                          
  C4-A1        REM           187                  3.84   1.01   382       3.86               1.04   243    3.63   1.00    2.809   4.09    0.017                                          0.073

One-Way ANOVA on z-score standardized measurements; SD: standard deviation; df: degrees of freedom (between groups, within groups); Adjusted p-value by sex, age, BMI and European ancestry proportion in general linear models.

^a^ Bonferroni *post hoc* test for AG x GG: p = 0.041

^b^ Bonferroni *post hoc* test for AG x GG: p = 0.023

^c^ Bonferroni *post hoc* test for AA x GG: p = 0.018; for AG x GG: p = 0.020

Discussion {#sec009}
==========

Several previous studies revealed the interaction of Homer proteins with metabotropic glutamate receptors and the potential role of these proteins in the trafficking and/or clustering of the receptors in various cell types \[[@pone.0223632.ref004],[@pone.0223632.ref020]--[@pone.0223632.ref023]\]. Studies interfering with the normal expression of *HOMER* genes suggest the involvement of these gene products in animal behavior, from *Drosophila* to mammals \[[@pone.0223632.ref005]\]. Also, genetic variation in *HOMER1* seem to be associated with drug dependency and abuse \[[@pone.0223632.ref011]\] and mental disease \[[@pone.0223632.ref010]\].

In the present study, we report the association between rs3822568 in the *HOMER1* gene with sleep latency, sleep efficiency, number of arousals per hour, AHI and theta spectral power in healthy subjects. The analyzed SNP consists of a genetic variant found at the 3' untranslated region (3'UTR) of the *HOMER1* gene, for which the ancestral allele is a guanine (G) and the alternative allele is an adenine (A).

Here, we found that homozygous individuals for the G allele, on average, experience higher sleep latency times, lower sleep efficiency, less arousals per hour and lower AHI than subjects carrying the A allele. This suggests that the presence of the G allele is associated with changes in sleep onset ‒ leading to the higher latency times ‒ but not the sleep maintenance ‒ since no associations with arousals per hour were found. In this sense, the observed lower sleep efficiency might be attributed to the long sleep latency rather than to a higher sleep fragmentation caused by many arousals during the sleep time \[[@pone.0223632.ref024],[@pone.0223632.ref025]\].

On the other hand, even if AHI is a common measure for the diagnosis and severity determination of OSAS, rs3822568 did not show any association with the presence of the syndrome according to the definitions we used \[[@pone.0223632.ref015]\]. This corroborates that other factors besides the genetic background might influence the manifestation of the obstructive sleep apnea syndrome, such as environmental and developmental factors \[[@pone.0223632.ref026]\]. Another aspect that needs to be taken in consideration is that the definition of hypopnea is not consensual among sleep researches \[[@pone.0223632.ref027]\], and some studies suggest than an AHI cutoff of 5 is too low, especially for elderly people \[[@pone.0223632.ref028]\]. Moreover, we also observed that gender, age, BMI and genetic ancestry might influence the association between the investigated polymorphism and sleep traits, except sleep latency.

It is known that oscillations in the sleep EEG reflect the homeostatic regulation of sleep \[[@pone.0223632.ref029]\]. Common variation in genes involved in sleep homeostasis has been associated with sleep-related traits. Mazzotti and colleagues \[[@pone.0223632.ref016]\] found an association between a SNP in the adenosine deaminase gene and higher delta and theta EEG spectral powers, indicating a higher sleep intensity in carriers of the alternative allele. In our investigation, we observed that GG genotype carriers showed, on average, lower theta spectral power in stages 1, 2 and REM sleep ‒ the associations remained significant only in the occipital derivations and in stage 1 and REM sleep after the adjustment for potential confounders ([Table 2](#pone.0223632.t002){ref-type="table"}). These findings add on the results regarding the association between GG genotype and lower sleep efficiency, and suggests that changes in EEG power associated with this SNP might explain the differences found in sleep efficiency.

Naidoo and colleagues \[[@pone.0223632.ref030]\] demonstrated *Homer1* upregulation during wakefulness and its down regulation at sleep is not a simple correlate, but a matter of cause and effect. Using *Drosophila* and mouse models, these authors showed that *Homer1a/homer1a* knockout leads to reduced and fragmented sleep in flies, while it causes inability to sustain the wake state in the rodents. Thus, it is possible that genetic variation in the *Homer* genes could modulate the subtle balance of HOMER proteins in the regulation of glutamatergic neurotransmission and yield different states of neuronal excitability in the nervous system, affecting sleep.

Polymorphisms in the *Homer* genes could, therefore, modulate the interactions among HOMER proteins in regulating glutamatergic neurotransmission and yield different states of neuronal excitability in the nervous system affecting sleep state. Considering that the 3'UTR is a key post-transcriptional regulation site, figuring a target for non-coding RNA based regulatory mechanisms such as microRNAs \[[@pone.0223632.ref031]\], polymorphisms at the 3'UTR may lead to a differential regulation of gene expression \[[@pone.0223632.ref032]\]. This could explain the functional consequences of the studied SNP on variability of sleep-related traits presented in this study.

In the view of recent studies about glutamatergic neurotransmission, sleep homeostasis and synaptic plasticity, *Homer1* is strictly linked to the (mGluR5) function. It selectively uncouples mGluR5 from the effector targets in the postsynaptic density \[[@pone.0223632.ref033]\] that results in attenuation of mGluR5-mediated activation of phospholipase C and downstream signaling \[[@pone.0223632.ref034]\]. In humans, increased mGluR5 availability after sleep deprivation was tightly associated with increased propensity to fall asleep \[[@pone.0223632.ref035]\] and considering the interplay between *Homer1* and mGluR5, it has been suggested that *Homer1a* serves as a molecular integrator of arousal and sleep need \[[@pone.0223632.ref036]\]. In that way, we may cautionary propose the SNP described here could mediates the integration *Homer1*/mGluR5 through 3'UTR mechanisms cited above, and therefore would mediates a compensatory mechanism to promote wakefulness in the sleep-deprived state like insomnia states.

When considering that the relationship between disease susceptibility and genetic variation is complex, and for the most phenotypes more than one gene is generally involved, care has to be taken when considering just one SNP in one gene to draw conclusions about a complex and multifactorial phenotype as sleep. Nevertheless, when considering the physiological mechanisms related to glutamate neurotransmission and previous associations with sleep, *HOMER1* sounds like a good candidate gene for sleep phenotypes related to extended wake like insomnia.

*HOMER1* has many single nucleotide polymorphisms along its sequence. According to the 1000 Genomes Project data, in American populations rs3822568 is in strong linkage disequilibrium with at least five other SNPs **([S1 Fig](#pone.0223632.s001){ref-type="supplementary-material"})**, although all of them are localized in intergenic regions and therefore have low potential to yield genetic consequences. Also, neither of them has been associated with any relevant clinical phenotype. This fact does not exclude the possibility of other SNPs and even phased haplotypes play important roles in the genetic control of the sleep parameters analyzed in this study.

In this context, the present findings suggest that the rs3822568 polymorphism in the *HOMER1* gene is associated with impacts on sleep quality and sleep structure, as evidenced by higher sleep latency and lower EEG theta power in individuals carrying the GG genotype. Thus, this SNP may be an important source of variation in sleep homeostasis, probably due to the regulation of the glutamatergic signaling pathways.

Supporting information {#sec010}
======================

###### Haplotype and linkage disequilibrium (LD) map.

S1A Fig LD plot of six SNPs in *HOMER1* gene. Dark red shading denotes D\' values (i.e., 99 means D\' of 0.99). Squares with no numbers indicates D\' of 1. The numbers 1, 13, 22, 26, 55 and 67 in the first line indicate the position of the six strongest (D' ≥ 0.90) SNP linkage among 67 SNPs in the region. S1B Fig Inferred haplotypes for the LD block with frequencies). HaploView (version 4.2).
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Click here for additional data file.

We thank Luiz Otávio Bastos Esteves and Guilherme Silva Umemura for their assistance and comments that greatly improved the manuscript.

10.1371/journal.pone.0223632.r001

Decision Letter 0

Romigi

Andrea

Academic Editor

© 2020 Andrea Romigi

2020

Andrea Romigi

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

3 Mar 2020

PONE-D-19-26778

A single nucleotide polymorphism in the HOMER1 gene is associated with sleep latency and theta power in sleep electroencephalogram

PLOS ONE

Dear Prof Pedrazzoli,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Please consider the minor concerns highlighted by both reviewers: 

1) Better discuss that the study of only one gene (and one SNP) and the multifactoral phenotypes with possible multiple genetic factors 

==============================

We would appreciate receiving your revised manuscript by Apr 17 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Andrea Romigi, M.D., Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

 

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this study, the authors evaluated the association of a specific SNP in the HOMER1 gene with specific aspects of sleep in a representative sample of the Brazilian population. They in fact hypothesize that, given the importance of the glutamatergic system regulating sleep and prolonged wakefulness, genetic variation in the HOMER1 gene might explain inter-individual variability in several sleep traits measured using polysomnography.

Even if they studied only a gene and only one SNP of this gene, the study is well conducted and the sample size of studied subjects is consistent

The research is quite original, the experiments and the statistical analyses were conducted in a proper way and the paper is written in a clear and intelligible way.

Some minor issues are to be considered:

The author should better discuss that this study involve only one gene (and one SNP) but the phenotypes they are discussing is multifactorial and the genetic factors involved can be numerous. The gene they are studying may give a contribution but it does not explain the whole genetic variability of these phenotypes. They should also discuss about the possibility of other SNPs (and HAPLOTYPES) of this gene involved Are already known other SNPs? Could they sequence the entire gene in a group of subjects in order to study this variability and the existence of other SNPs? They should at least discuss it

They should also discuss about the functional role and meaning of the SNP they analyzed

Reviewer \#2: In the current manuscript Pedrazzoli et al., examine the association between overnight sleep parameters and a polymorphism in the Homer1 gene in a Brazilian population. The authors report significant genotype interactions in the Homer1 3\'UTR and sleep latency, efficiency and other parameters, as well as an interaction with Theta power in the EEG recordings. Recent studies have revealed genetic links with the Homer1 gene and psychiatric conditions. Basic research has also shown an important role for the Homer1 gene in sleep behavior in rodents and insects. The current work is presented in a straight forward manner and the data collection has been done rigorously and appropriately.

Considering the material covered in this manuscript it would be highly appropriate to include in the bibliography a recent high profile paper on the role of Homer1a in synaptic plasticity during sleep. (Diering et al., 2017 Science, PMID: 28154077). This paper shows that Homer1a protein is important to regulate mGluR1/5 signaling during sleep and for sleep-dependent remodeling of synapses. A second paper Holst et al., 2017 eLife, PMID: 28980941 shows that mGluR5 is upregulated during sleep deprivation in humans and is required for appropriate response to sleep deprivation in mice.

I have no other concerns about the current manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Graham Hugh Diering

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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\# EDITOR: To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

RESPONSE: The majority of our protocols involve standard methods such as the scores of polysomnography data and SNP genotyping. We have specified the thermal conditions in Material and Methods section ("rs3822568 Genotyping" subsection). We do not think it is necessary to specify other conventional protocols involved in our study.

\# REVIEWER 1: The author should better discuss that this study involve only one gene (and one SNP) but the phenotypes they are discussing is multifactorial and the genetic factors involved can be numerous. The gene they are studying may give a contribution but it does not explain the whole genetic variability of these phenotypes.

RESPONSE: Thank you for pointing it out. We have added a paragraph (L229-234) in Discussion section arguing about this matter:

"When considering that the relationship between disease susceptibility and genetic variation is complex, and for the most phenotypes more than one gene is generally involved, care has to be taken when considering just one SNP in one gene to draw conclusions about a complex and multifactorial phenotype as sleep. Nevertheless, when considering the physiological mechanisms related to glutamate neurotransmission and previous associations with sleep, HOMER1 sounds like a good candidate gene for sleep phenotypes related to extended wake like insomnia."

\# REVIEWER 1: They should also discuss about the possibility of other SNPs (and HAPLOTYPES) of this gene involved Are already known other SNPs? Could they sequence the entire gene in a group of subjects in order to study this variability and the existence of other SNPs? They should at least discuss it.

RESPONSE: We appreciate your suggestion. However, it is not possible at this time to sequence the samples. Therefore, we have added a supplemental material informing about the linkage disequilibrium (S1A Figure) and also a paragraph (L235-240) discussing the possibilities for other SNPs in HOMER1 gene that might have a role in the phenotype:

"HOMER1 has many single nucleotide polymorphisms along its sequence. According to the 1000 Genomes Project data, in American populations rs3822568 is in strong linkage disequilibrium with at least five other SNPs (S1 Figure), although all of them are localized in intergenic regions and therefore have low potential to yield genetic consequences. Also, neither of them has been associated with any relevant clinical phenotype. This fact does not exclude the possibility of other SNPs and even phased haplotypes play important roles in the genetic control of the sleep parameters analyzed in this study."

\# REVIEWER 1: They should also discuss about the functional role and meaning of the SNP they analyzed.

RESPONSE: Great point. We have added a new paragraph (L220-L228) in Discussion, which we cautionary suggest (L226-228) the role of rs3822568 in a physiological context:

"In the view of recent studies about glutamatergic neurotransmission, sleep homeostasis and synaptic plasticity, Homer1 is strictly linked to the (mGluR5) function. It selectively uncouples mGluR5 from the effector targets in the postsynaptic density (33) that results in attenuation of mGluR5-mediated activation of phospholipase C and downstream signaling (34). In humans, increased mGluR5 availability after sleep deprivation was tightly associated with increased propensity to fall asleep (35) and considering the interplay between Homer1 and mGluR5, it has been suggested that Homer1a serves as a molecular integrator of arousal and sleep need (36). In that way, we may cautionary propose the SNP described here could mediates the integration Homer1/mGluR5 through 3'UTR mechanisms cited above, and therefore would mediates a compensatory mechanism to promote wakefulness in the sleep-deprived state like insomnia states."

\#REVIEWER 2: In the current manuscript Pedrazzoli et al., examine the association between overnight sleep parameters and a polymorphism in the Homer1 gene in a Brazilian population. The authors report significant genotype interactions in the Homer1 3\'UTR and sleep latency, efficiency and other parameters, as well as an interaction with Theta power in the EEG recordings. Recent studies have revealed genetic links with the Homer1 gene and psychiatric conditions. Basic research has also shown an important role for the Homer1 gene in sleep behavior in rodents and insects. The current work is presented in a straight forward manner and the data collection has been done rigorously and appropriately.

Considering the material covered in this manuscript it would be highly appropriate to include in the bibliography a recent high profile paper on the role of Homer1a in synaptic plasticity during sleep. (Diering et al., 2017 Science, PMID: 28154077). This paper shows that Homer1a protein is important to regulate mGluR1/5 signaling during sleep and for sleep-dependent remodeling of synapses. A second paper Holst et al., 2017 eLife, PMID: 28980941 shows that mGluR5 is upregulated during sleep deprivation in humans and is required for appropriate response to sleep deprivation in mice.

I have no other concerns about the current manuscript.

RESPONSE: Thank you for the suggestion. We have added a new paragraph (L220-L228) in Discussion with references suggested above and other:

"In the view of recent studies about glutamatergic neurotransmission, sleep homeostasis and synaptic plasticity, Homer1 is strictly linked to the (mGluR5) function. It selectively uncouples mGluR5 from the effector targets in the postsynaptic density (33) that results in attenuation of mGluR5-mediated activation of phospholipase C and downstream signaling (34). In humans, increased mGluR5 availability after sleep deprivation was tightly associated with increased propensity to fall asleep (35) and considering the interplay between Homer1 and mGluR5, it has been suggested that Homer1a serves as a molecular integrator of arousal and sleep need (36). In that way, we may cautionary propose the SNP described here could mediates the integration Homer1/mGluR5 through 3'UTR mechanisms cited above, and therefore would mediates a compensatory mechanism to promote wakefulness in the sleep-deprived state like insomnia states."
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Dear Dr. Pedrazzoli,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Andrea Romigi, M.D., Ph.D

Academic Editor
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A single nucleotide polymorphism in the *HOMER1* gene is associated with sleep latency and theta power in sleep electroencephalogram

Dear Dr. Pedrazzoli:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Andrea Romigi

Academic Editor

PLOS ONE
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